22159-Breast Cancer-NA-596

Breast Cancer

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

  • Details

ClinicalTrials.gov ID: NCT05501886
Diagnosis Type: NA
USOR Number:

  • Address

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

Search by practice name, trial titles, indicators and specific disease types.